MENTOR, Ohio — Jackson Callahan has been playing football since he was three or four years old. The love for the game runs deep—deep enough to carry him through one of childhood's toughest battles. At ...
New research from Memorial Sloan Kettering Cancer Center (MSK) reports encouraging results for a new liposarcoma treatment; describes more potent CAR T cells that can be given at lower doses; relates ...
Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials In this pilot study, we assessed the ...
SEQUIM — It was a massage therapist who first noticed the lump behind Rod Dirks’ left knee. Odd, but probably nothing to worry about, right? After all, Dirks was in his mid-30s – a young, active ...
NEW YORK – When the US Food and Drug Administration approved Tecelra (afamitresgene autoleucel) in August 2024 for certain patients with advanced sarcoma, Adaptimmune became the second company to ever ...
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor ...
ABSTRACT: Background: The low-grade fibromyxoid sarcoma (LGFMS) is an exceptionally uncommon sarcoma that primarily manifests in the extremities or trunk of young adults, presenting as painless ...
ABSTRACT: Background: The low-grade fibromyxoid sarcoma (LGFMS) is an exceptionally uncommon sarcoma that primarily manifests in the extremities or trunk of young adults, presenting as painless ...
Following strong treatment response data for Adaptimmune’s lete-cel, the biotech is planning to initiate a rolling BLA submission to the FDA, set to start by the end of 2025. Adaptimmune Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results